D rug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight loss results comparable to those of popular GLP-1 injectables like ...

Novo Nordisk said it is now planning to advance both subcutaneous and oral formulations of amycretin into additional clinical trials. The new data follows another study that showed the ...

Data on the subcutaneous version of amycretin is due next year, and Novo Nordisk also presented early data on another oral therapy, CBR1 inverse agonist monlunabant (INV-202), which showed a 3% ...

Novo Nordisk shares have dropped ~50% since June ... Despite strong market share and promising early results for Amycretin, competition from Eli Lilly and regulatory risks pose significant challenges.

The early data from UBT251 suggests it may be as similarly fast-acting as another of Novo Nordisk’s obesity hopefuls, the oral GLP-1 and amylin receptor amycretin, which showed 13.1% weight loss ...

The topline results from the Phase 1b/2a clinical trial showed that patients treated with Amycretin achieved ... vice president for Development at Novo Nordisk. "The results seen in the trial ...

Novo Nordisk NVO shares have lost 15.2% so far ... In January, the company reported that patients receiving the highest dose of amycretin experienced a 22% weight loss compared with a gain in ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading ... profile similar to tirzepatide increases the importance of amycretin as a next-gen molecule to sustain the obesity franchise in ...